Important: This is a sample of the policy document. To determine the precise terms, conditions and exclusions of your cover, please refer to the actual policy and any endorsement issued to you.

# **Conditions for Lady 360**

# Your policy

Lady 360 is a plan specifically designed to meet the protection needs of women. It provides cover for death, specific female illnesses, and surgery as well as support after specific diagnosis or surgery and health screening for the insured every two years, as set out below.

# **1** What your policy covers

We will pay according to the **benefit table** if a claim arises from an insured event during the **contract term**. You can claim for more than one insured event from Female illnesses benefit, Female surgeries benefit and Support benefit, up to the cover limit as set out in the benefit table below. However, it must not be for the same illness, surgery or cause (except for cancer).

If we pay a claim that is less than the cover limit for Female illnesses benefit, Female surgeries benefit and Support benefit, we will reduce the percentage of the sum assured we will pay for that benefit with this amount.

This policy will end when:

- the total claims paid for the insured events under Female illnesses benefit amounts to 100% of the sum assured, under Female surgeries benefit, amounts to 50% of the sum assured and under Support benefit amounts to 100% of sum assured; or
- we pay the death benefit; whichever happens first.

Benefit table	
Category of insured	Cover limit
events	
1. Death benefit	S\$10,000
2. Female illnesses	
benefit (The total	
amount paid under this	
benefit will not be more	
than 100% of the sum	
assured.)	100% of the sum
Chronic autoimmune	assured
hepatitis	
Malignant cancer of	
female sites	
Rheumatoid arthritis	
SLE with lupus	
nephritis <ul> <li>Carcinoma-in-situ of</li> </ul>	50% of the sum
female sites	assured
Osteoporotic fractures	assureu
of the hip and vertebra	
requiring surgery or	
repair	
3. Waiver of premium	Waive (not
on Female illnesses	charge) premiums
benefit	for 24 months if
	<b>you</b> make a
	successful claim
	for any of the
	covered female
	illnesses under
	Female illnesses
-	benefit.
4. Female surgeries	50% of the sum
benefit (The total	assured
amount paid under this	
benefit will not be more	
than 50% of the sum	
assured.)	
Radical vulvectomy     Worthoim's operation	
Wertheim's operation     Uterus, total pelvic	
Uterus, total pelvic     exenteration	
exemileration	

Catagory of incurad	Cover limit
Category of insured events	Cover limit
<ul> <li>Breast lumpectomy –</li> </ul>	30% of the sum
bilateral	assured
<ul> <li>Mastectomy – bilateral</li> </ul>	
or unilateral	
<ul> <li>Hysterectomy</li> </ul>	
<ul> <li>Complicated repair of</li> </ul>	
fistula	
<ul> <li>Breast lumpectomy –</li> </ul>	15% of the sum
unilateral	assured
<ul> <li>Urinary incontinence</li> </ul>	
requiring surgery	
<ul> <li>Uterine prolapse</li> </ul>	
requiring surgery	
<ul> <li>Thyroid disorders</li> </ul>	
requiring surgery	
<ul> <li>Polycystic ovarian</li> </ul>	
syndrome requiring	
surgery	
5. Support benefit	100% of the sum
(The total amount paid	assured
under this benefit will	
not be more than 100%	
of the sum assured.)	
<ul> <li>Reconstructive surgery</li> </ul>	
benefit due to	
mastectomy following	
breast cancer or	
carcinoma-in-situ of the	
breast, malignant skin	
cancer, accidental burns	
and accident	
<ul> <li>Oocyte</li> </ul>	25% of the sum
cryopreservation	assured
benefit	
<ul> <li>Breast cancer –</li> </ul>	15% of the sum
molecular gene	assured (up to a
expression profiling test	maximum of
for treatment guidance	S\$7,500)
benefit	
Outpatient psychiatric	5% of the sum
benefit	assured
Hormone replacement	5% of the sum
therapy benefit	assured

Category of insured events	Cover limit
6. Care benefit	Available every
Health screening benefit	two years from
	the second policy
	anniversary of
	the cover start
	date.

#### a Death benefit

If the insured dies during the term of the policy, **we** will pay a death benefit of \$\$10,000.

The policy will end when **we** make this payment.

#### b Female illnesses benefit

If the insured is diagnosed by a **registered medical practitioner** with any of the covered female illnesses shown in the benefit table, **we** will pay this benefit up to the limit shown in the benefit table. The total amount **we** will pay under this benefit will not be more than 100% of the sum assured.

**You** can claim for each female illness only once, except for cancer. **You** can claim more than once for cancer in the situations below.

- If the subsequent claim for cancer is a recurrence of the cancer of any previous claim for cancer (for which we have paid a benefit), the next claim for cancer will be covered only if the recurrence of cancer is first diagnosed after a five-year cancer-free period.
- If the subsequent claim for cancer is not a recurrence of the cancer of any previous claim for cancer (for which we have paid a benefit), we will cover the next claim for cancer only if the cancer is first diagnosed at least one year after the date of the first diagnosis of the cancer of the last claim for cancer (for which we paid a benefit).

#### Example 1:

You claimed carcinoma-in-situ of the left breast. We paid 50% of the sum assured. Five years after the diagnosis, you are diagnosed with carcinomain-situ of the left breast again. We will pay you 50% of the sum assured again. Because we have 100% of the sum assured, the Female illnesses benefit ends.

#### Example 2:

You claimed carcinoma-in-situ of the left breast. We paid 50% of the sum assured. Two years after the diagnosis, carcinoma-in-situ of the left breast cancer is diagnosed again. In this instance, the breast cancer recurred before the **five-year cancer-free period**, so **we** will not pay anything.

#### Example 3:

You claimed carcinoma-in-situ of the left breast. We paid 50% of the sum assured. Five years after the diagnosis, you are diagnosed with advance stage breast cancer that spreads and invades surrounding tissues. You claimed under malignant cancer of the female site. Even though the cover limit for malignant cancer of the female site is 100%, we will pay 50% of the sum assured. This is because the total benefit we will pay for Female illnesses benefit is 100%. Because we have paid a total of 100% of the sum assured, the Female illnesses benefit ends.

#### Example 4:

You claimed carcinoma-in-situ of the left breast. We paid 50% of the sum assured. One year after the diagnosis, you are diagnosed with carcinomain-situ of ovaries and it is proven not to be a recurrence of the breast cancer. We will pay 50% of the sum assured. Because we have paid a total of 100% of the sum assured, the Female illnesses benefit ends.

If more than one condition is diagnosed in any of the **paired organs** on the same date, though they may exist in different stages or forms, **we** will only pay the benefit relating to one of these conditions. In this situation, **we** will pay the highest benefit amount. **We** will pay this benefit only if the insured survives for at least seven days after the diagnosis of the covered female illness.

The **Female illnesses benefit** will end when **we** have paid 100% of the sum assured.

## c Waiver of premium on Female illnesses benefit

If **you** make a successful claim for any of the covered female illnesses, **you** will not have to continue to pay the premiums on the policy for the next 24 months or until the end of the **contract term**, whichever is earlier.

**We** will waive (not charge) premiums that are due after the diagnosis date of any of the covered female illnesses.

You can claim this benefit only once.

#### d Female surgeries benefit

If the insured had a female surgery shown in the benefit table, **we** will pay this benefit up to the limit shown in the benefit table. The most **we** will pay under this benefit is 50% of the sum assured.

#### Example:

You claimed 15% of the sum assured for thyroid disorders needing surgery. You can still claim 35% of the sum assured under this benefit. You claimed again for Werthiem's operation. We will pay you the remaining 35% of the sum assured. Because we have paid a total of 50% of the sum assured, the Female surgeries benefit ends.

The surgery must be considered medically necessary by a **registered medical practitioner** and be done in a hospital in Singapore.

If the insured had multiple female surgeries due to the same condition, **we** will only pay for one female surgery which has the highest benefit limit.

**You** can claim for each female surgery only once, except for surgeries due to cancer. **You** can claim more than once for surgery due to cancer in the situations below.

- If the subsequent claim for surgery due to cancer is a recurrence of the cancer of any previous claim for cancer (for which we have paid a benefit), we will cover the subsequent claim for cancer only if the recurrence of cancer is first diagnosed after a five-year cancer-free period.
- If the subsequent claim for surgery due to cancer is not a recurrence of the cancer of any previous claim for cancer (for which we have paid benefit), we will cover the subsequent claim for cancer only if the cancer is first diagnosed at least one year after the date of first diagnosis of the cancer of the last claim for cancer (for which we paid a benefit).

If more than one condition is diagnosed in any of the **paired organs** on the same date, though they may exist in different stages or forms, **we** will only pay the benefit relating to one of these conditions. In this situation, **we** will pay the highest benefit amount.

The **Female surgeries benefit** will end when **we** have paid 50% of the sum assured.

## e Support benefit

If the insured claimed for any of the insured events under **Support benefit**, **we** will pay this benefit up to the limit shown in the benefit table. The most **we** will pay under this benefit is 100% of the sum assured.

i. Reconstructive surgery benefit due to mastectomy following breast cancer or carcinoma-in-situ of the breast,

# malignant skin cancer, accidental burns and accident

If the insured had a reconstructive surgery due to a mastectomy following breast cancer or carcinoma-in-situ of the breast, malignant skin cancer, **accidental burns** or **accident**, **we** will pay 100% of the sum assured. The reconstructive surgery must be certified by a **registered medical practitioner** and be done in a hospital in Singapore.

You must claim for reconstructive surgery within 365 days from the date of diagnosis of the breast cancer or carcinoma in situ of the breast, malignant skin cancer, accidental burns or from the date of the accident.

## ii. Oocyte cryopreservation benefit

If the insured between the age of 15 and 40 years had oocyte cryopreservation treatment before chemotherapy or radiotherapy (not including target therapy) to treat cancer, we will pay 25% of the sum assured. The chemotherapy or radiotherapy treatment must be recommended by a registered medical practitioner.

We will pay this benefit only once.

## iii. Breast cancer – molecular gene expression profiling test for treatment guidance benefit

If the insured has a molecular gene expression profiling test, **we** will pay 15% of the sum assured, up to S\$7,500. The insured must be diagnosed with breast cancer and had undergone surgical excision of an early stage malignant breast tumour. This test must be recommended and done by a **registered medical practitioner.** 

We will pay this benefit only once.

#### iv. Outpatient psychiatric benefit

If the insured is diagnosed with major depressive disorder or anxiety disorder due to **traumatic life events**, we will pay 5% of the sum assured. The insured must be diagnosed with the mental health condition by a registered psychiatrist in Singapore and must be under medication prescribed by a registered psychiatrist in Singapore for at least six continuous months.

We will pay this benefit only once.

v. Hormone replacement therapy benefit
 We will pay 5% of the sum assured if it is certified by a registered medical practitioner that it is medically necessary for the insured who is under the age of 50 years to be on hormone replacement therapy as a result of a bilateral oophorectomy or hysterectomy (or both).

We will pay this benefit only once.

The **Support benefit** will end when **we** have paid 100% of the sum assured.

#### Example:

You claimed 5% of the sum assured for hormone replacement therapy. You can still claim 95% of the sum assured under the Support benefit. You claimed again for reconstructive surgery due to malignant skin cancer. We will pay you 95% of the sum assured. Because we have paid 100% of the sum assured, the Support benefit ends.

#### f Care benefit

We provide the insured with a health screening benefit every two years. This benefit is available from the second policy **anniversary** of the **cover start date**. We will write to **you** when this benefit is due. You cannot transfer this benefit and the health screening must be completed within 180 days from the date we write to you and carried out at any one of our panel of clinics listed on our letter to you. You can find the list of tests provided under this benefit on our website.

We will not provide this benefit if:

- there are outstanding premiums due under this policy; or
- the policy has ended.

## 2 Our responsibilities to you

The **contract term** will give details of how long this policy applies for.

If your **contract term** is up to age 64, **we** will cover the insured up to the **anniversary** immediately after the insured's 64<sup>th</sup> birthday.

If your policy is on a 10-year renewable **contract term**, **we** will:

- renew the policy for the same contract term and sum assured, if there is no claim under your policy during the contract term;
- renew the policy up to the anniversary immediately after the insured's 64<sup>th</sup> birthday if the policy is renewed on or after the insured's 45<sup>th</sup> birthday;
- ask you to pay the premium based on the policy's renewal term, sum assured and the age of the insured at the time the policy is renewed.

## **3** Your responsibilities

**You** will pay **your** first premium at the time **you** apply for this policy. **You** will then pay future

premiums when they are due. **You** will have 30 days as a period of grace to make these payments for this policy to continue. If **we** are due to pay any benefits during this period, **we** will take off any unpaid premiums from the benefits.

If **you** still have not paid the premium after the period of grace, this policy will end.

If this policy ends because **you** have not paid the premium, **you** can reinstate it within 36 months by paying the premiums **you** owe along with interest. This applies as long as **you** give **us** satisfactory proof of the insured's good health and there is no change in the risks covered by this policy.

If **you** cancel your policy before the nextpremium is due, **we** will end your policy from the next premium due date and **we** will not refund any unused premium.

The premium that **you** pay for this policy is not guaranteed. **We** will give **you** at least six months' notice before **we** make any change.

# 4 What you need to be aware of

#### a Suicide

This policy is not valid if the insured commits suicide within one year from the **cover start date**.

We will refund the total premiums paid, without interest, less any payout and any amount you owe us, from the cover start date.

#### **b** Insured events

We only cover the insured events we list in the benefit table. The name of each insured event is only a guide to what is covered. The full definition of each insured event covered and the circumstances in which **you** can claim are given in this policy.

You must provide adequate medical evidence and we may ask the insured to have a medical examination by a doctor we have appointed. Every diagnosis must be supported by acceptable clinical, radiological, historical and laboratory evidence and confirmed by a registered medical practitioner.

We will not pay if your claim arises from:

- deliberate acts such as self-inflicted injuries, illnesses or attempted suicide;
- deliberate misuse of drugs or alcohol;
- acquired immunodeficiency syndrome (AIDS), AIDS-related complex or infection by human immunodeficiency virus (HIV), resulting from any means;
- cosmetic or plastic surgery or any treatment solely for the purpose of beautification; or
- a Female illnesses benefit, a Waiver of premium on Female illnesses benefit, a Female surgeries benefit, or a Support benefit (other than reconstructive surgery benefit due to accidental burns or accident, or outpatient psychiatric benefit due to disfigurement from accidental burns or death of the insured's husband, wife or child), if the insured suffered symptoms of, had investigations for, or was diagnosed with, the illnesses or conditions at any time before or within 90 days after the cover start date. For Female surgeries benefit and Support **benefit**, the date of diagnosis will be the date the medical condition that leads to the surgery, test or therapy is diagnosed, and not the date of the surgery, test or therapy. For outpatient psychiatric benefit, the date of diagnosis will be the date the heart attack of specified severity, end stage kidney failure, stroke with permanent neurological deficit, major cancer, or loss of independent existence is diagnosed.

#### Making a claim С

We must be told within six months after the diagnosis or the event giving rise to the claim.

When we pay a claim, we will not refund premiums paid.

#### Refusing to pay a claim d

After you have been continuously covered for one year from the cover start date, we will pay your claim unless:

- it is a case of fraud;
- your policy has ended;
- the insured has a material pre-existing condition which was not revealed to us when you applied for this policy; or
- the claim is excluded or not covered under the terms of the policy.

#### Transferring the legal right of the policy е

You cannot assign (transfer) this policy unless you tell us in writing and we agree to the assignment.

#### f **Excluding third-party rights**

Anyone not directly involved in this policy cannot enforce it under the Contracts (Rights of Third Parties) Act 2001.

#### 5 Definitions

Accident and accidental mean an unexpected incident that results in an injury or death. The injury or death must be caused entirely by being hit by an external object that produces a bruise or wound, except for injury or death caused specifically by drowning, food poisoning, choking

on food, or suffocation by smoke, fumes or gas.

Accidental burns means accidental third degree (full thickness of the skin) burns covering at least 10% of the surface of the insured's body as measured by the Lund and Browder Body Surface Chart.

Anniversary means the last day of every 12 months from the entry date of the policy.

Contract term means the contract term (or term) shown in the policy schedule (or endorsement) to this policy.

Cover start date means the date:

- we issue the policy;
- we issue an endorsement to include or increase a benefit; or
- we reinstate the policy; whichever is latest.

Material pre-existing condition means any condition that existed before the cover start date which would have reasonably affected our decision to accept your application and for which:

- the insured had symptoms that would have • caused any sensible person to get medical treatment, advice or care;
- treatment was recommended by or received from a medical practitioner; or
- the insured had medical tests or investigations.

Paired organs refers to those organs with both left and right parts (including but not limited to breast, fallopian tube, kidney, ovary), the left organ and right organ (paired organ) will be considered as one and the same organ.

Recurrence of the cancer means a subsequent cancer is caused by:

- (i) the same malignant cells that caused the relevant previous cancer; or
- (ii) metastasis of the relevant previous cancer; if there has been more than one claim for cancer.

**Relevant previous cancer** means the cancer of the last claim for cancer (for which **we** have paid a benefit which causes a **recurrence of the cancer** in the subsequent claim for cancer.

**Registered medical practitioner** means a doctor who is qualified in western medicine and is legally licensed in Singapore or has the qualifications recognised by the Singapore Medical Council.

We, us, our means Income Insurance Limited.

**You** means the policyholder shown in the policy schedule.

Five-year cancer-free period means that the insured's treating specialist (or specialists) who is also a registered medical practitioner confirms that the insured has been cancer-free. in terms of the relevant previous cancer for the whole of the last five-year period after the relevant previous cancer. This period of being cancer-free must also be confirmed and supported by clinical, radiological, histological and laboratory evidence, and evidence of all other relevant investigative methods available at that time. The five-year cancer-free period will start on the date all treatments for the relevant previous cancer, have been completed. These treatments include any surgery, chemotherapy, radiation therapy, immunotherapy, monoclonal antibody therapy and other conventional cancer treatments that have been used as prescribed by the insured's treating specialist.

# 6 Definition of insured events

6.1	Chronic autoimmune hepatitis
Female illnesses	A chronic necro-inflammatory liver disorder of unknown cause associated with
benefit	circulating auto-antibodies and a high serum globulin level. The following
	criteria for a valid claim must all be satisfied.
	• hypergammaglobulinaemia: the presence of at least one of the following auto- antibodies :
	<ul> <li>Anti-Nuclear Antibody;</li> </ul>
	<ul> <li>Anti-smooth muscle antibodies;</li> </ul>
	<ul> <li>Anti-actin antibodies;</li> </ul>
	<ul> <li>Anti-LKM-1 antibodies.</li> </ul>
	• Liver biopsy confirmation of the diagnosis of auto-immune hepatitis.
	• The diagnosis of auto-immune hepatitis must be confirmed by a hepatologist.
	Malignant cancer of female sites
	A malignant tumour characterized by the uncontrolled growth and spread of
	malignant cells and the invasion of tissue to any of the following sites: breast,
	cervix uteri, uterus, ovary, fallopian tube, vagina and vulva.
	This excludes secondary cancer, which has originated from other organs and
	spread to the female genital tract and breast, non-invasive cancer-insitu, and tumours in the presence of any human immunodeficiency virus (HIV).
	Diagnosis must be supported by histological evidence of malignancy. Diagnosis has to be confirmed by appropriate medical specialist.
	Rheumatoid arthritis
	Rheumatoid arthritis means widespread joint destruction with major clinical deformity of 3 or more of the following joint areas: hands, wrists, elbows, cervical spine, knees, ankles, metatarsophalangeal joints in the feet.
	Only severe cases of rheumatoid arthritis are covered. The condition must result in the inability of the insured to perform (whether aided or unaided) at least 3 out of 6 "Activities of Daily Living" for a continuous period of at least 6 months.
	Activities of Daily Living: (i) Washing - the ability to wash in the bath or shower (including getting into and
	out of the bath or shower) or wash satisfactorily by other means;

6.1	(ii) Dressing - the ability to put on, take off, secure and unfasten all garmen	ts
Female illnesses	and, as appropriate, any braces, artificial limbs or other surgical appliances;	
benefit	(iii) Transferring - the ability to move from a bed to an upright chair or	
benefit	wheelchair and vice versa;	
	(iv) Mobility - the ability to move indoors from room to room on level surface	
	(v) Toileting - the ability to use the lavatory or otherwise manage bowel an	
	bladder functions so as to maintain a satisfactory level of personal hygiene;	
	(vi) Feeding - the ability to feed oneself once food has been prepared and m	iade
	available.	
	For the purpose of this definition, "aided" shall mean with the aid of specia	I
	equipment, device and/or apparatus and not pertaining to human aid.	
	Diagnosis has to be confirmed by appropriate medical specialist.	
	Systemic lupus erythematosus (SLE) with lupus nephritis	
	The unequivocal diagnosis of Systemic Lupus Erythematosus (SLE) based	d on
	recognised diagnostic criteria and supported with clinical and labora	
	evidence. In respect of this contract, systemic lupus erythematosus wil	l be
	restricted to those forms of systemic lupus erythematosus which involve	the
	kidneys (Class III to Class VI Lupus Nephritis, established by renal biopsy, ar	าd in
	accordance with the RPS/ISN classification system). The final diagnosis mus	
	confirmed by a certified doctor specialising in Rheumatology and Immunology	ogy.
	The RPS/ISN classification of lupus nephritis:	
	Class I Minimal mesangial lupus nephritis	
	Class II Mesangial proliferative lupus nephritis	
	Class III Focal lupus nephritis (active and chronic; proliferative and	
	sclerosing)	
	Class IV Diffuse lupus nephritis (active and chronic; proliferative and	
	sclerosing; segmental and global)	
	Class V Membranous lupus nephritis	
	Class VI Advanced sclerosis lupus nephritis	
	Carcinoma-in-situ of female sites	
	Carcinoma-in-situ (CIS) means the focal autonomous new growth	of
	•	
	carcinomatous cells confined to the cells in which it originated and has not	-
	resulted in the invasion and/ or destruction of surrounding tissues. 'Invas	
	means an infiltration and/or active destruction of normal tissue beyond	
	basement membrane. Only CIS of the breast, cervix uteri, uterus, fallopian t	ube,
	ovary, and vagina/vulva will be covered.	
	The diagnosis of the CIS must always be supported by a histopathological rep	
	Furthermore, the diagnosis of CIS must always be positively diagnosed upon	the

6.1 Female illnesses benefit	basis of a microscopic examination of the fixed tissue, supported by a biopsy result. Clinical diagnosis does not meet this standard.
benefit	CIS of ovaries should be capsule intact, with no tumour on the ovarian surface, classified as T1aN0M0 (TNM classification) or FIGO 1A (International Federation of Gynecology and Obstetrics).
	CIS of fallopian tube should be limited to the tubal mucosa and classified as Tis according to the TNM staging method.
	CIS of vagina/ vulva should be classified as Tis according to the TNM staging method or FIGO 0 according to the method of the FIGO.
	Clinical Intraepithelial Neoplasia (CIN) classification including CIN I, CIN II, and CIN III (severe dysplasia without CIS) and all CIS in the presence of any human immunodeficiency virus (HIV) are specifically excluded.
	Octoonovertic fractiones of the his and vertakes requiring concerns or reacin
	Osteoporotic fractures of the hip and vertebra requiring surgery or repair
	A condition of reduced bone mass with decreased cortical thickness and a decrease in the number and size of the trabeculae of cancellous bone (but
	normal chemical composition, resulting in increased fracture incidence).
	Osteoporosis is defined as having a bone mineral density which is at least 2.5 standard deviation below the young mean of the population.
	Only osteoporotic fractures of the hip and vertebra requiring surgery or repair are covered.
	Diagnosis has to be confirmed by appropriate medical specialist.
6.2	Radical vulvectomy
Female surgeries benefit	The complete removal of the vulva and the pelvic lymph nodes.
	Diagnosis has to be confirmed by appropriate medical specialist.
	peivic lymph hodes.
	Diagnosis has to be confirmed by appropriate medical specialist.
	Uterus, total pelvic exenteration
	adnexa, the pelvic and lower sigmoid colon, pelvic lymph nodes and all the pelvic
	peritoneum, due to gynecological cancers.
	<u>Uterus, total pelvic exenteration</u> Actual undergoing of excision of the bladder, lower uterus, vagina uterus, adnexa, the pelvic and lower sigmoid colon, pelvic lymph nodes and all the pelvic

	Diagnosis has to be confirmed by appropriate medical specialist.
6.2 Female surgeries benefit	<b>Breast lumpectomy - bilateral</b> Removal of a malignant tumour or carcinoma-in-situ and surrounding breast tissue in both breasts.
	Diagnosis has to be confirmed by appropriate medical specialist.
	<u>Mastectomy – bilateral/ unilateral</u> Mastectomy for the treatment of a malignant tumour or carcinoma-in-situ of the breast. Lumpectomy will not be covered.
	Diagnosis has to be confirmed by appropriate medical specialist.
	Mastectomy – bilateral shall mean a surgical operation to remove the entire breast on both sides.
	Mastectomy - unilateral shall mean a surgical operation to remove the entire breast on one side.
	<b><u>Hysterectomy</u></b> The removal of the uterus (at least the corpus and cervix or corpus only) with supporting evidence of carcinoma of the uterus, fallopian tube, ovary, vagina or endometrium, advanced cervical carcinoma, or hydatidiform mole.
	Diagnosis has to be confirmed by appropriate medical specialist.
	<b><u>Complicated repair of fistula</u></b> Actual undergoing abdominal or vaginal repair of ureterovaginal, vesicovaginal, urethrovaginal or complex fistulas which occurred following cancer-related pelvic surgery or in case of advanced pelvic malignancy, especially when there has been radiotherapy.
	Repair of fistula resulting from trauma (an obstetric tear or extension of an episiotomy), diverticular disease, Crohn's disease, or any other non-cancer related pelvic surgery would not be covered.
	Diagnosis has to be confirmed by appropriate medical specialist.
	Breast lumpectomy – unilateral Removal of a malignant tumour or carcinoma-in-situ and surrounding breast tissue in one breast.
	Diagnosis has to be confirmed by appropriate medical specialist.
	Diagnosis has to be confirmed by appropriate medical specialist. <u>Breast lumpectomy – unilateral</u> Removal of a malignant tumour or carcinoma-in-situ and surrounding breast tissue in one breast.

	Urinary incontinence requiring surgery
	Urinary incontinence requiring surgery is a condition where all of the following
	diagnostic conditions are met:
6.2	• Urinary incontinence has been diagnosed and under the management of a
Female surgeries	registered medical practitioner for at least 6 months during which time, there
benefit	has been a need for continuous incontinence medical treatment; and
	• Medically necessary surgical repair has been undertaken for the sole purpose
	of correcting the incontinence.
	Surgery that includes treatment for other pathology including a hysterectomy
	for uterus pathology or dysfunction, does not meet this condition.
	Diagnosis has to be confirmed by appropriate medical specialist.
	Uterine prolapse requiring surgery
	Uterine prolapse/pelvic relaxation requiring surgery is a condition where all of the following diagnostic conditions are met:
	• Uterine prolapse/pelvic relaxation has been diagnosed and under the
	management of a registered medical practitioner for at least 2 years during
	which time, there has been a need for the continuous use of management
	devices (vaginal pessary); and
	• Medically necessary surgical repair has been undertaken for the sole purpose
	of correcting the loosening of the support muscles and tissues in the pelvic area.
	Surgery that includes treatment for other pathology including hysterectomy for
	uterus pathology or dysfunction does not meet this condition.
	Diagnosis has to be confirmed by appropriate medical specialist.
	Thyroid disorders requiring surgery
	Surgical procedures involving partial or total removal of the thyroid gland due
	to thyroid cancer, multinodular goiter compressing nearby structure.
	Diagnosis has to be confirmed by appropriate medical specialist.
	Surgery related to thyroid nodule or cosmetic or thyroidotomy are excluded.
	Polycystic ovarian syndrome requiring surgery
	Actual undergoing of medically necessary laparoscopic ovarian drilling for
	treatment of infertility due to Polycystic ovarian syndrome as certified by
	specialist obesterician/ gynaecologist.

6.3	Reconstructive surgery benefit due to mastectomy following breast cancer or
Support benefit	carcinoma-in-situ of the breast, malignant skin cancer, accidental burns and
	accident
	Due to mastectomy following breast cancer or carcinoma-in-situ of the breast
	Plastic or reconstructive surgery of the breast performed by a registered
	surgeon after mastectomy following diagnosis of breast cancer or carcinoma-in-
	situ of the breast.
	Due to malignant skin cancer
	The undergoing of skin grafting due to removal of the following malignant skin
	cancer:
	<ul> <li>Non-melanoma skin cancer with evidence of metastasis to lymph node or beyond</li> </ul>
	<ul> <li>Malignant melanoma that has caused invasion beyond epidermis</li> </ul>
	Due to accidental burns
	The undergoing of skin transplantation due to <b>accidental burns.</b>
	Due to accident
	The undergoing of plastic or reconstructive surgery (restoration or
	reconstruction of the shape and appearance of facial structures which are
	defective, missing, damaged or misshapen) performed under general anesthesia
	by a registered surgeon to correct facial disfiguration caused by <b>accident</b> .
	Reconstruction surgery of breast, skin or any other body part for cosmetic
	purposes only is excluded.
	Oocyte cryopreservation benefit
	This benefit pays an amount specified in the benefit table if the insured has
	utilized service for cryopreservation of mature oocytes (eggs) or embryos
	between age 15 to 40 before chemotherapy or radiotherapy following diagnosis
	of cancer and is prescribed to undergo chemotherapy or radiotherapy for
	cancer, provided that this contract remains in force. Target therapy is excluded.
	Outpatient neuchistric honofit
	Outpatient psychiatric benefit Upon diagnosis of the insured suffering from major depressive disorder (MDD)
	and anxiety disorders due to a <b>traumatic life event</b> . The covered conditions
	must be diagnosed by a registered psychiatrist and the insured must be under
	medication prescribed by a registered psychiatrist and the insured must be under medication prescribed by a registered psychiatrist for at least six continuous
	months. Any other mental health conditions will not be payable.
	,

Support benefit	(1) insured was diagnosed with heart attack of specified severity, end stage
	kidney failure, stroke with permanent neurological deficit, major cancer or
	loss of independent existence;
	(2) insured was disfigured due to accidental burns; or
	(3) death of the insured's spouse or child.
	Heart Attack of Specified Severity
	Death of heart muscle due to ischaemia, that is evident by at least three of the
	following criteria proving the occurrence of a new heart attack:
	History of typical chest pain;
	• New characteristic electrocardiographic changes; with the development of any of the following: ST elevation or depression, T wave inversion, pathological Q waves or left bundle branch block;
	• Elevation of the cardiac biomarkers, inclusive of CKMB above the generally accepted normal laboratory levels or Cardiac Troponin T or I at 0.5ng/ml and above;
	<ul> <li>Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality. The imaging must be done by Cardiologist specified by the Company.</li> </ul>
	<ul><li>For the above definition, the following are excluded:</li><li>Angina;</li></ul>
	Heart attack of indeterminate age; and
	• A rise in cardiac biomarkers or Troponin T or I following an intra-arterial cardiac procedure including, but not limited to, coronary angiography and coronary angioplasty.
	Explanatory note: 0.5ng/ml = 0.5ug/L = 500pg/ml
	End stage kidney failure
	Chronic irreversible failure of both kidneys requiring either permanent renal dialysis or kidney transplantation.
	Stroke with permanent neurological deficit
	A cerebrovascular incident including infarction of brain tissue, cerebral and
	subarachnoid haemorrhage, intracerebral embolism and cerebral thrombosis
	resulting in permanent neurological deficit. This diagnosis must be supported by
	all of the following conditions:
	<ul> <li>Evidence of permanent clinical neurological deficit confirmed by a neurologist at least 6 weeks after the event; and</li> </ul>
	<ul> <li>Findings on Magnetic Resonance Imaging, Computerised Tomography, or other reliable imaging techniques consistent with the diagnosis of a new stroke.</li> </ul>

6.3	The following are excluded:
Support benefit	Transient Ischaemic Attacks;
	<ul> <li>Brain damage due to an accident or injury, infection, vasculitis, and inflammatory disease;</li> </ul>
	<ul> <li>Vascular disease affecting the eye or optic nerve;</li> </ul>
	<ul> <li>Ischaemic disorders of the vestibular system; and</li> </ul>
	• Secondary haemorrhage within a pre-existing cerebral lesion.
	Permanent means expected to last throughout the lifetime of the insured.
	Permanent neurological deficit means symptoms of dysfunction in the nervous system that are present on clinical examination and expected to last throughout the lifetime of the insured. Symptoms that are covered include numbness, paralysis, localized weakness, dysarthria (difficulty with speech), aphasia (inability to speak), dysphagia (difficulty swallowing), visual impairment, difficulty in walking, lack of coordination, tremor, seizures, dementia, delirium and coma.
	<b>Major Cancer</b> A malignant tumour positively diagnosed with histological confirmation and characterized by the uncontrolled growth of malignant cells with invasion and destruction of normal tissue.
	The term Major Cancer includes, but is not limited to, leukemia, lymphoma and sarcoma.
	Major Cancer diagnosed on the basis of finding tumour cells and/or tumour- associated molecules in blood, saliva, faeces, urine or any other bodily fluid in the absence of further definitive and clinically verifiable evidence does not meet the above definition.
	For the above definition, the following are excluded:
	<ul> <li>All tumours which are histologically classified as any of the following: Pre-malignant; Non-invasive;</li> </ul>
	Carcinoma-in-situ (Tis) or Ta;
	Having borderline malignancy;
	Having any degree of malignant potential;
	Having suspicious malignancy;
	Neoplasm of uncertain or unknown behavior; or
	All grades of dysplasia, squamous intraepithelial lesions (HSIL and LSIL) and intra epithelial neoplasia;

6.3	• Any non-melanoma skin carcinoma, skin confined primary cutaneous
Support benefit	lymphoma and dermatofibrosarcoma protuberans unless there is
	evidence of metastases to lymph nodes or beyond;
	<ul> <li>Malignant melanoma that has not caused invasion beyond the anidermic.</li> </ul>
	<ul><li>epidermis;</li><li>All Prostate cancers histologically described as T1N0M0 (TNM)</li></ul>
	Classification) or below; or Prostate cancers of another equivalent or
	lesser classification;
	<ul> <li>All Thyroid cancers histologically classified as T1N0M0 (TNM Classification) or below;</li> </ul>
	<ul> <li>All Neuroendocrine tumours histologically classified as T1N0M0 (TNM)</li> </ul>
	Classification) or below;
	• All tumours of the Urinary Bladder histologically classified as T1N0M0
	(TNM Classification) or below;
	All Gastro-Intestinal Stromal tumours histologically classified as Stage I
	or IA according to the latest edition of the AJCC Cancer Staging Manual, or below;
	<ul> <li>Chronic Lymphocytic Leukaemia less than RAI Stage 3;</li> </ul>
	All bone marrow malignancies which do not require recurrent blood
	transfusions, chemotherapy, targeted cancer therapies, bone marrow
	transplant, haematopoietic stem cell transplant or other major interventionist treatment; and
	<ul> <li>All tumours in the presence of HIV infection</li> </ul>
	Loss of Independent Existence
	A condition as a result of a disease, illness or injury whereby the insured is
	unable to perform (whether aided or unaided) at least 3 of the following 6 "Activities of Daily Living", for a continuous period of 6 months.
	, retrictes of barry living , for a continuous period of o months.
	Activities of Daily Living:
	(i) Washing - the ability to wash in the bath or shower (including getting into and
	out of the bath or shower) or wash satisfactorily by other means; (ii) Dressing - the ability to put on, take off, secure and unfasten all garments
	and, as appropriate, any braces, artificial limbs or other surgical appliances;
	(iii) Transferring - the ability to move from a bed to an upright chair or
	wheelchair and vice versa;
	(iv) Mobility - the ability to move indoors from room to room on level surfaces;
	(v) Toileting - the ability to use the lavatory or otherwise manage bowel and
	bladder functions so as to maintain a satisfactory level of personal hygiene;
	(vi) Feeding - the ability to feed oneself once food has been prepared and made available.
	This condition must be confirmed by the company's approved doctor.
	Non-organic diseases such as neurosis and psychiatric illnesses are excluded.

1	
	For the purpose of this definition, "aided" shall mean with the aid of special
	equipment, device and/or apparatus and not pertaining to human aid.
	Hormone replacement therapy benefit This benefit pays for hormone replacement therapy (HRT) advised in women
	under the age of 50 years as a result of a bilateral oophorectomy or
	hysterectomy (or both). The indication for the HRT should be deemed medically
	necessary, prescribed for a minimum of one year after the oophorectomy or
	hysterectomy (or both) and certified by the appropriate treating specialist. The
	claim should be supported by evidence of bilateral oophorectomy or
	hysterectomy (or both), mammogram, pap smear and other investigations done
	for screening before starting the HRT, minimum of 06 consecutive prescriptions
	by the treating specialist.
	This benefit excludes local HRT like vaginal products, nasal sprays.
	Breast cancer – molecular gene expression profiling test for treatment
	guidance benefit This benefit pays an amount specified in the policy to assist with covering the
	expenses of a molecular gene expression profiling test if the insured undergoes
	surgical excision of an early stage malignant breast tumour and is deemed eligible for such testing by their treating oncologist. For the early stage
	surgical excision of an early stage malignant breast tumour and is deemed
	surgical excision of an early stage malignant breast tumour and is deemed eligible for such testing by their treating oncologist. For the early stage
	surgical excision of an early stage malignant breast tumour and is deemed eligible for such testing by their treating oncologist. For the early stage malignant breast tumour to be eligible the tumour has to be confirmed as
	surgical excision of an early stage malignant breast tumour and is deemed eligible for such testing by their treating oncologist. For the early stage malignant breast tumour to be eligible the tumour has to be confirmed as estrogen receptor positive on immunohistochemistry testing and without any spread of the tumour to the lymph nodes.
	<ul><li>surgical excision of an early stage malignant breast tumour and is deemed eligible for such testing by their treating oncologist. For the early stage malignant breast tumour to be eligible the tumour has to be confirmed as estrogen receptor positive on immunohistochemistry testing and without any spread of the tumour to the lymph nodes.</li><li>A gene expression profiling test analyzes the patterns of a number of different</li></ul>
	<ul><li>surgical excision of an early stage malignant breast tumour and is deemed eligible for such testing by their treating oncologist. For the early stage malignant breast tumour to be eligible the tumour has to be confirmed as estrogen receptor positive on immunohistochemistry testing and without any spread of the tumour to the lymph nodes.</li><li>A gene expression profiling test analyzes the patterns of a number of different genes within the cancer cell to help predict how likely it is that an early-stage,</li></ul>
	<ul> <li>surgical excision of an early stage malignant breast tumour and is deemed eligible for such testing by their treating oncologist. For the early stage malignant breast tumour to be eligible the tumour has to be confirmed as estrogen receptor positive on immunohistochemistry testing and without any spread of the tumour to the lymph nodes.</li> <li>A gene expression profiling test analyzes the patterns of a number of different genes within the cancer cell to help predict how likely it is that an early-stage, hormone-sensitive breast cancer will recur after initial treatment and is used in</li> </ul>
	<ul><li>surgical excision of an early stage malignant breast tumour and is deemed eligible for such testing by their treating oncologist. For the early stage malignant breast tumour to be eligible the tumour has to be confirmed as estrogen receptor positive on immunohistochemistry testing and without any spread of the tumour to the lymph nodes.</li><li>A gene expression profiling test analyzes the patterns of a number of different genes within the cancer cell to help predict how likely it is that an early-stage, hormone-sensitive breast cancer will recur after initial treatment and is used in an attempt to determine the right treatment for the right person with early-</li></ul>
	<ul> <li>surgical excision of an early stage malignant breast tumour and is deemed eligible for such testing by their treating oncologist. For the early stage malignant breast tumour to be eligible the tumour has to be confirmed as estrogen receptor positive on immunohistochemistry testing and without any spread of the tumour to the lymph nodes.</li> <li>A gene expression profiling test analyzes the patterns of a number of different genes within the cancer cell to help predict how likely it is that an early-stage, hormone-sensitive breast cancer will recur after initial treatment and is used in</li> </ul>